AGPAT2 Human shRNA Plasmid Kit (Locus ID 10555)

CAT#: TL314894

AGPAT2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 10555
• Synonyms: 1-AGPAT2; BSCL; BSCL1; LPAAB; LPAAT-beta
• Vector: pGFP-C-shLenti
• E. coli Selection: Chloramphenicol (34 ug/ml)
• Mammalian Cell Selection: Puromycin
• Format: Lentiviral plasmids
• Kit Components: AGPAT2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 10555). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_001012727, NM_006412, NM_006412.1, NM_006412.2, NM_006412.3, NM_001012727.1, BC000026, BC004529, BC004529.2, BC007269, BC019292, NM_001012727.2, NM_006412.4
• UniProt ID: O15120
• Summary: This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).